Form 8-K
8-K — BioNexus Gene Lab Corp
Accession: 0001477932-26-004556
Filed: 2026-07-28
Period: 2026-07-28
CIK: 0001737523
SIC: 8071 (SERVICES-MEDICAL LABORATORIES)
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — bglc_8k.htm (Primary)
EX-99.1 — PRESS RELEASE (bglc_ex991.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — FORM 8-K
8-K (Primary)
Filename: bglc_8k.htm · Sequence: 1
bglc_8k.htm
0001737523false00017375232026-07-282026-07-28iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 28, 2026
BioNexus Gene Lab Corp.
(Exact name of Company as specified in its charter)
Wyoming
001-41750
35-2604830
(State or other jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification Number)
Unit A-28-7, Tower A, Menara UOA Bangsar,
No.5 Jln Bangsar Utama 1,
59000 Kuala Lumpur, Malaysia
(Address of principal executive offices)
Phone: +1 (307) 241-6898
(Company’s Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, no par value
BGLC
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events
On July 28, 2026, BioNexus Gene Lab Corp. (the “Company”) issued a press release titled “BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit,” announcing continued progress toward commercializing the VitaGuard™ molecular residual disease (“MRD”) platform in Southeast Asia following a recent working visit to facilities of the Tongshu Gene group in Shanghai and Changzhou, China. The press release describes technical and commercial planning, selected hospital site visits in China, and the Company’s next steps for laboratory implementation, validation, regulatory preparation and commercialization in Southeast Asia, as well as Fidelion Diagnostics Pte. Ltd.’s efforts to pursue opportunities in other international markets.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 8.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release dated July 28, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BioNexus Gene Lab Corp.
/s/ Su-Leng Tan Lee
By:
Su-Leng Tan Lee
Chief Executive Officer
Date:
July 28, 2026
3
EX-99.1 — PRESS RELEASE
EX-99.1
Filename: bglc_ex991.htm · Sequence: 2
bglc_ex991.htm
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
Meetings in Shanghai and Changzhou link VitaGuard's commercial use in China with BioNexus' Southeast Asian plans and Fidelion's international licensing efforts
KUALA LUMPUR, Malaysia, July 28, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”) today announced continued progress toward commercializing the VitaGuard™ molecular residual disease (“MRD”) platform in Southeast Asia following a recent working visit to facilities of the Tongshu Gene group (“Tongshu Gene”) in Shanghai and Changzhou, China, led by Dr. Muthu Meyyappan, Chief Commercial Officer of Fidelion Diagnostics Pte. Ltd. (“Fidelion”). The visit combined technical planning with meetings at selected Chinese hospitals where VitaGuard is in paid commercial use.
VitaGuard is a tumor‑naive, fixed‑panel liquid‑biopsy platform that uses next‑generation sequencing to look for circulating tumor DNA (“ctDNA”) associated with MRD in solid tumors. The system combines blood stabilization, cell‑free DNA extraction, targeted sequencing, bioinformatics and reporting that can track molecular changes over time. Unlike patient‑specific tests that first require a panel designed from tumor tissue, VitaGuard uses a fixed panel intended to make repeat blood‑based monitoring simpler to deploy. For BioNexus, the platform offers a direct path into precision oncology in Southeast Asia and, through its investment in Fidelion, exposure to opportunities in other international markets.
During the working sessions, the teams reviewed what will be needed to implement VitaGuard in Southeast Asia under the existing assignment and license agreements. They covered laboratory workflows, documentation, reagents and system requirements, local implementation and commercial coordination.
The teams also discussed routes to market, including territorial licensing, laboratory partnerships, pharmaceutical collaborations and other strategic relationships.
According to Tongshu Gene, VitaGuard is currently used on a paid commercial basis at numerous hospitals across China. Dr. Meyyappan and the Fidelion team visited selected sites and met physicians and laboratory personnel who use the platform. Their feedback was positive and gave the team a closer look at how VitaGuard fits into day‑to‑day workflows. These visits were not a formal clinical evaluation.
“Working alongside the Tongshu Gene team and hearing directly from physicians made the visit especially useful,” said Sam Tan, Chief Executive Officer of BioNexus. “We came away with a better sense of how VitaGuard is being used in China and what it will take to bring it to new markets. BioNexus will lead that effort in Southeast Asia, while Fidelion pursues opportunities elsewhere.”
VitaGuard grew out of the Tongshu Gene group's liquid‑biopsy and molecular‑diagnostics program. Tongshu Gene's work on the platform includes patent filings dating from at least 2018, proprietary reagents and panels, and clinical‑research collaborations. In November 2025, Wuxi Tongshu Biotechnology Co., Limited, the contracting company within the Tongshu Gene group, assigned the VitaGuard intellectual‑property rights outside the People's Republic of China to Fidelion.
1
In the ten Southeast Asian markets specified in BioNexus' license, the Company's exclusive rights cover the use, development, manufacture, marketing, distribution and sale of VitaGuard‑based products and services. BioNexus may also pursue local regulatory approvals and other commercial relationships in those markets and, with Fidelion's prior written consent as required under the license, grant sublicenses.
BioNexus also owns approximately 15% of Fidelion.
Together, the license and investment give BioNexus two paths to participate in VitaGuard's growth: directly through its Southeast Asian business and indirectly through Fidelion's licensing and partnerships elsewhere.
BioNexus has previously said it expects VitaGuard's cost per test to be under US$300, before local pricing, reimbursement and implementation considerations. If achieved, management believes this cost profile could make repeat molecular monitoring more accessible in cost‑sensitive healthcare systems. MRD monitoring can involve testing at several points during and after treatment, creating the potential for repeat test volumes rather than a one‑time diagnostic event. Together, BioNexus' ten licensed markets have a population of more than 680 million people, providing a large regional base as the Company pursues approved indications, clinical adoption and market access.
“VitaGuard gives BioNexus a practical entry into precision oncology,” Mr. Tan continued. “In Southeast Asia, we can build the business under our license. Elsewhere, our investment in Fidelion gives us a stake in the value created as partnerships develop. The China visit moved us from contractual rights to the work of implementation.”
Dr. Meyyappan leads Fidelion's international commercialization program and has spent more than 15 years working across precision oncology, liquid biopsy, MRD testing, genomic analysis, next‑generation sequencing and bioinformatics.
Before joining Fidelion, he held global commercial leadership roles at Menarini Silicon Biosystems, Congenica and Variantyx, as well as senior genomics roles at QIAGEN and BIOBASE. His work has taken him across North America, Europe and Asia, helping bring complex genomic technologies into laboratory and clinical settings.
Dr. Meyyappan holds a Ph.D. in Cancer Biology from the University of Calgary and a Bachelor of Science in Biotechnology from Rochester Institute of Technology.
“Speaking directly with physicians using VitaGuard was especially valuable,” said Dr. Meyyappan. “Their feedback was positive, and seeing the platform in day‑to‑day use gave us practical insight. I have spent much of my career helping laboratories and clinical partners adopt complex genomic technologies, and VitaGuard will require the same disciplined, market‑by‑market approach.”
Following the visit, BioNexus and Fidelion are advancing the transfer and localization of operating documentation, planning for local laboratory verification and validation, and regulatory and commercial preparation in Malaysia and Singapore. Subject to completion of this work and applicable approvals, BioNexus continues to target initial deployment in select Southeast Asian medical hubs during 2026.
At the same time, Fidelion is engaged in discussions with prospective licensing, laboratory, pharmaceutical and commercial partners for markets outside Southeast Asia. No definitive agreement has been executed.
2
Market entry will depend on completing the necessary laboratory, validation and regulatory work. Any future partnership will be subject to negotiation and definitive documentation, with material agreements disclosed as required.
“The visit put the next steps in plain view,” Mr. Tan concluded. “Tongshu Gene brings the technical and manufacturing experience, Fidelion holds the international rights, and BioNexus knows the region. Our job now is to turn that combination into a working Southeast Asian business.”
About BioNexus Gene Lab Corp.
BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a technology‑focused company operating across biotechnology, precision diagnostics and specialty materials. Through its subsidiaries, investments and licensing arrangements, the Company is developing new healthcare and life‑science businesses alongside its established operations.
BioNexus holds exclusive commercialization rights for the VitaGuard™ MRD platform in the ten Southeast Asian markets specified in its regional license and an equity interest of approximately 15% in Fidelion Diagnostics.
For more information, please visit www.bionexusgenelab.com.
About Fidelion Diagnostics
Fidelion Diagnostics Pte. Ltd. is a precision‑diagnostics company based in Singapore and focused on developing international markets for VitaGuard. Fidelion holds assigned VitaGuard intellectual‑property rights outside the People's Republic of China and is pursuing licensing, laboratory, clinical and pharmaceutical partnerships.
For more information, please visit www.fideliondx.com.
Forward‑Looking Statements
This press release contains forward‑looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about the continued transfer, localization, verification, validation and operational implementation of VitaGuard; planned laboratory, regulatory and commercialization activities in Southeast Asia, including the timing of initial deployments and the Company's ability to build a regional cancer‑monitoring business; VitaGuard's expected cost profile, potential accessibility, suitability for repeat longitudinal monitoring and potential to generate repeat test volumes; the scale and development of the opportunity in the licensed markets; Fidelion's pursuit of international licensing, laboratory, pharmaceutical and strategic relationships; the ability to apply experience from VitaGuard's commercial use in China to other markets; and the potential strategic or economic value to BioNexus of its Southeast Asian rights and equity interest in Fidelion.
Forward‑looking statements may be identified by words such as “believe,” “expect,” “intend,” “plan,” “advance,” “potential,” “may,” “will,” “positioned,” “opportunity” and similar expressions. These statements reflect management's present expectations based on information currently available and assumptions management believes are reasonable.
Actual future results may differ materially due to factors including completion and localization of technical documentation; laboratory implementation and the ability to complete jurisdiction‑specific analytical verification and clinical validation; differences among product configurations and between the Chinese market and other jurisdictions; the timing and outcome of regulatory reviews; the ability to identify, negotiate and complete agreements with qualified commercial partners; the ability to achieve the expected cost profile; pricing and reimbursement conditions; approved indications, testing frequency and adoption of MRD and liquid‑biopsy technologies in clinical workflows; manufacturing, reagent and supply‑chain readiness; intellectual‑property protection; competition; access to capital; and the performance of contractual counterparties.
Additional risks and uncertainties are described in BioNexus' most recent Annual Report on Form 10‑K, subsequent Quarterly Reports on Form 10‑Q and other filings with the Securities and Exchange Commission. Forward‑looking statements speak only as of the date made, and BioNexus undertakes no obligation to update them except as required by law.
Investor Relations
BioNexus Gene Lab Corp.
ir@bionexusgenelab.com
3
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 9
v3.26.1
Cover
Jul. 28, 2026
Cover [Abstract]
Entity Registrant Name
BioNexus Gene Lab Corp.
Entity Central Index Key
0001737523
Document Type
8-K
Amendment Flag
false
Entity Emerging Growth Company
true
Document Period End Date
Jul. 28, 2026
Entity Ex Transition Period
false
Entity File Number
001-41750
Entity Incorporation State Country Code
WY
Entity Tax Identification Number
35-2604830
Entity Address Address Line 1
Unit A-28-7, Tower A
Entity Address Address Line 2
Menara UOA Bangsar
Entity Address Address Line 3
No.5 Jln Bangsar Utama 1
Entity Address City Or Town
Kuala Lumpur
Entity Address Postal Zip Code
59000
City Area Code
307
Local Phone Number
241-6898
Security 12b Title
Common Stock, no par value
Trading Symbol
BGLC
Security Exchange Name
NASDAQ
Entity Address Country
MY
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 3 such as an Office Park
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine3
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
ISO 3166-1 alpha-2 country code.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCountry
Namespace Prefix:
dei_
Data Type:
dei:countryCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details
Name:
dei_EntityExTransitionPeriod
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration